{"entity":{"id":"nct06074588","kind":"trial","name":"Sacituzumab Tirumotecan (MK-2870) Versus Chemotherapy in Previously Treated Advanced or Metastatic Nonsquamous Non-small Cell Lung Cancer (NSCLC) With","aka":[],"tldr":"A phase 3 trial of Sacituzumab tirumotecan, Docetaxel, Pemetrexed in non-small-cell lung cancer and small-cell lung cancer, run by Merck Sharp & Dohme LLC, active and no longer recruiting.","summary":"Sacituzumab Tirumotecan (MK-2870) Versus Chemotherapy in Previously Treated Advanced or Metastatic Nonsquamous Non-small Cell Lung Cancer (NSCLC) With EGFR Mutations or Other Genomic Alterations (MK-2870-004). ClinicalTrials.gov record last updated 2026-08-14: active not recruiting. Enrollment is planned at 556 participants. Primary completion is estimated at 2027-05-10. No tabular results are posted on ClinicalTrials.gov; this does not exclude separate publications. Registered interventions: Sacituzumab tirumotecan, Docetaxel, Pemetrexed. Registered primary measures: Overall Survival (OS) of Participants with NSCLC with Epidermal Growth Factor Receptor (EGFR) Mutations.","status":"active","asOf":"2026-10-06","links":[{"label":"ClinicalTrials.gov NCT06074588","url":"https://clinicaltrials.gov/study/NCT06074588"}],"tags":["ctgov-ingest"],"related":[],"cancers":["nsclc","sclc","egfr-mutant-nsclc"],"sections":[],"technologies":["adc","cytotoxic-chemotherapy","topoisomerase-inhibitors"],"targets":["trop2"],"drugs":["sacituzumab-tirumotecan","docetaxel","pemetrexed"],"companies":["merck"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["ClinicalTrials.gov record last updated 2026-08-14: active not recruiting. Enrollment is planned at 556 participants. Primary completion is estimated at 2027-05-10. No tabular results are posted on ClinicalTrials.gov; this does not exclude separate publications."],"nct":"NCT06074588","phase":"3","setting":"Sacituzumab Tirumotecan (MK-2870) Versus Chemotherapy in Previously Treated Advanced or Metastatic Nonsquamous Non-small Cell Lung Cancer (NSCLC) With EGFR Mutations or Other Genomic Alterations (MK-2870-004)","sponsor":"Merck Sharp & Dohme LLC","participation":[{"nct":"NCT06074588","source":"https://clinicaltrials.gov/study/NCT06074588","fetchedAt":"2026-10-07T16:54:09.016Z","studySha256":"a0b3f91955124e28578195385f684bef478495758602eb7e775b51d08e9a3320","overallStatus":"ACTIVE_NOT_RECRUITING","lastUpdatePosted":"2026-08-14","leadSponsor":"Merck Sharp & Dohme LLC","collaboratorCount":0,"minimumAge":"18 Years","sex":"ALL","healthyVolunteers":false,"hasEligibility":true,"enrolment":556,"enrolmentType":"ESTIMATED","siteCount":195,"recruitingSiteCount":0,"countries":["Australia","Brazil","Canada","Chile","China","Czechia","France","Germany","Greece","Hong Kong","Israel","Italy","Japan","Malaysia","Mexico","Philippines","Poland","South Korea","Spain","Taiwan","Thailand","Turkey (Türkiye)","United Kingdom","United States","Vietnam"]}],"started":"2023-11-12","startedType":"actual","enrolled":556,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct06074588/","neighbours":{"cancer":[{"id":"egfr-mutant-nsclc","kind":"cancer","name":"EGFR-mutated non-small-cell lung cancer","route":"/cancers/egfr-mutant-nsclc/"},{"id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/"},{"id":"sclc","kind":"cancer","name":"Small-cell lung cancer","route":"/cancers/sclc/"}],"technology":[{"id":"adc","kind":"technology","name":"Antibody-drug conjugate (ADC)","route":"/technologies/adc/"},{"id":"cytotoxic-chemotherapy","kind":"technology","name":"Cytotoxic chemotherapy","route":"/technologies/cytotoxic-chemotherapy/"},{"id":"topoisomerase-inhibitors","kind":"technology","name":"Topoisomerase-I inhibitors (and ADC payloads)","route":"/technologies/topoisomerase-inhibitors/"}],"target":[{"id":"trop2","kind":"target","name":"TROP2","route":"/targets/trop2/"}],"drug":[{"id":"docetaxel","kind":"drug","name":"Docetaxel","route":"/drugs/docetaxel/"},{"id":"pemetrexed","kind":"drug","name":"Pemetrexed","route":"/drugs/pemetrexed/"},{"id":"sacituzumab-tirumotecan","kind":"drug","name":"Sacituzumab tirumotecan","route":"/drugs/sacituzumab-tirumotecan/"}],"company":[{"id":"merck","kind":"company","name":"Merck & Co. (MSD)","route":"/companies/merck/"}]}}